Multisystem inflammatory syndrome in adults: A rare sequela of SARS-CoV-2 infection

Faran Ahmad, Arslan Ahmed, Sanu S. Rajendraprasad, Austin Loranger, Sonia Gupta, Manasa Velagapudi, Renuga Vivekanandan, Joseph A. Nahas, Robert Plambeck, Douglas Moore

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Multisystem inflammatory syndrome in adults (MIS-A) came to attention back in June 2020, when the United States Center for Disease Control and Prevention (CDC) received initial reports regarding patients who had presented delayed and multisystem involvement of the disease, with clinical course resembling multisystem inflammatory syndrome in children (MIS-C). This study introduces a case of MIS-A, where the patient presented 3 weeks after initial COVID-19 exposure. His clinical course was consistent with the working definition of MIS-A as specified by the CDC. Aggressive supportive care in the intensive care unit, utilization of advanced heart failure devices, and immunomodulatory therapeutics (high-dose steroids, anakinra, intravenous immunoglobulin) led to clinical recovery. Management of MIS-A is a topic of ongoing research and needs more studies to elaborate on treatment modalities and clinical predictors.

Original languageEnglish (US)
Pages (from-to)209-211
Number of pages3
JournalInternational Journal of Infectious Diseases
StatePublished - Jul 2021

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Multisystem inflammatory syndrome in adults: A rare sequela of SARS-CoV-2 infection'. Together they form a unique fingerprint.

Cite this